Radiation Therapy in Treating Women With Early Stage Breast Cancer

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Rutgers, The State University of New Jersey ( University of Medicine and Dentistry of New Jersey )
ClinicalTrials.gov Identifier:
First received: May 28, 2009
Last updated: August 23, 2013
Last verified: August 2013

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy in different ways may kill more tumor cells. Giving it after surgery may kill any tumor cells that remain after surgery.

PURPOSE: This phase II trial is studying the side effects of radiation therapy and to see how well it works in treating women with early stage breast cancer.

Condition Intervention Phase
Breast Cancer
Radiation: External beam boost
Radiation: whole breast irradiation
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Safety and Feasibility of Accelerated, Hypofractionated Radiotherapy in Women With Breast Cancer: A Phase II Trial

Resource links provided by NLM:

Further study details as provided by Rutgers, The State University of New Jersey:

Primary Outcome Measures:
  • Loco-regional control as assessed by physical examination, mammography, and other relevant imaging [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Toxicity (including seroma formation, brachial plexopathy, fat necrosis, pain, pigmentation, and telangiectasia) as assessed by NCI CTCAE v3.0 [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
  • Cosmesis as assessed by the Breast Cancer Treatment Outcome Scale [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 83
Study Start Date: June 2009
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Intervention Details:
    Radiation: External beam boost
    3-dimensional conformal radiation therapy and intensity modulated radiation therapy
    Radiation: whole breast irradiation
    accelerated, hypofractionated whole breast irradiation
Detailed Description:



  • To determine the freedom from local and regional failure in women with early stage breast cancer treated with accelerated, hypofractionated radiotherapy.
  • To determine the acute and late toxicity of accelerated, hypofractionated radiotherapy using previously published toxicity scales.


  • To measure cosmesis using the Harvard cosmesis scale in patients who have undergone lumpectomy.
  • To identify co-variates responsible for poor cosmetic outcome in these patients.

OUTLINE: Patients who have undergone lumpectomy undergo either intracavitary balloon brachytherapy boost and hypofractionated, accelerated whole breast irradiation (AWBI) OR 3D-conformal radiotherapy (3D-CRT)/intensity-modulated radiotherapy (IMRT) boost and AWBI. Patients who have undergone mastectomy undergo hypofractionated, accelerated chest wall irradiation.

  • Intracavitary balloon brachytherapy boost and AWBI (post-lumpectomy): Patients undergo intracavitary balloon brachytherapy boost twice daily for 2 days (total of 4 fractions). Beginning 5-21 days after completion of brachytherapy, patients undergo AWBI once daily 5 days a week for approximately 2 weeks (total of 11 fractions).
  • 3D-CRT/IMRT boost and AWBI (post-lumpectomy): Patients undergo 3D-CRT/IMRT boost twice daily for 2 days (total of 4 fractions). Patients also undergo AWBI as above before or after boost radiotherapy.
  • Accelerated chest wall irradiation (post-mastectomy): Patients undergo accelerated chest wall irradiation once daily 5 days a week for approximately 2 weeks (total of 11 fractions).

Patients who have undergone lumpectomy undergo frontal digital photography of the breasts at baseline, immediately before the initiation of radiotherapy, and then annually for 3 years after completion of radiotherapy. These patients also complete the Breast Cancer Treatment Outcome Scale at baseline and at 3 years after completion of radiotherapy. Physicians complete the Harvard Cosmesis scale at baseline and at 1 and 3 years after completion of radiotherapy.

After completion of study treatment, patients are followed up at weeks 1, 4, and 8 and then every 4 months for 2 years, every 6 months for 3 years, and annually thereafter.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Histologically confirmed breast cancer, including 1 of the following subtypes:

    • Ductal carcinoma in situ
    • Invasive ductal carcinoma
    • Invasive lobular carcinoma
    • Medullary carcinoma
    • Papillary carcinoma
    • Colloidal (mucinous) carcinoma
    • Tubular carcinoma
  • Pathological stage 0-IIIA disease (pTis; pT1-2, N0-N2a, M0)

    • Tumor size ≤ 5 cm
  • Breast considered technically satisfactory for radiotherapy
  • Has undergone lumpectomy or mastectomy and either sentinel node biopsy or axillary dissection (if invasive carcinoma is present)

    • Negative inked histological margins (i.e., no invasive cells at surgical margin) or confirmed negative re-excision specimen
  • Unifocal or multifocal (confined to 1 quadrant; tumors < 4 cm apart) disease with 1 or 2 foci that can be encompassed by 1 lumpectomy
  • No proven multicentric carcinoma (tumors in different quadrants of the breast or tumor separated by ≥ 4 cm) with other clinically or radiographically suspicious areas in the ipsilateral breast unless confirmed to be negative for malignancy by biopsy
  • No evidence of suspicious microcalcifications in the breast before the start of radiotherapy

    • If malignancy-associated microcalcifications were initially present, the post-excision mammography must be negative
  • No more than 9 positive axillary lymph nodes
  • No palpable or radiographically suspicious contralateral axillary, supraclavicular, infraclavicular, or internal mammary nodes unless there is histologic confirmation that these nodes are negative for tumor
  • No previously treated contralateral breast cancer or synchronous ipsilateral breast cancer
  • No lobular carcinoma in situ alone (i.e., no invasive component) or non-epithelial breast malignancies (e.g., sarcoma or lymphoma)
  • No Paget disease of the nipple
  • No skin involvement, regardless of tumor size
  • No distant metastases
  • Hormone receptor status not specified


  • Pre- or post-menopausal
  • ECOG performance status 0-1
  • No co-existing medical condition that would limit life expectancy to < 2 years
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No other malignancy within the past 5 years except for nonmelanoma skin cancer (the disease-free interval from any prior malignancy must be continuous)
  • No collagen vascular disease, specifically systemic lupus erythematosus, scleroderma, or dermatomyositis
  • No psychiatric or addictive disorder that would preclude obtaining informed consent


  • See Disease Characteristics
  • No prior radiotherapy for the current breast cancer
  • No tylectomies so extensive that the cosmetic result is low or poor prior to radiotherapy
  • Chemotherapy allowed provided the following criteria are met:

    • Chemotherapy is not administered prior to, during, and for ≥ 21 days after completion of radiotherapy (for patients receiving brachytherapy boost)
    • Chemotherapy is not administered for ≥ 21 days before, during, and for ≥ 21 days after completion of radiotherapy (for patients receiving external beam radiotherapy boost or chest wall irradiation)
  • Concurrent tamoxifen, anastrozole, or other hormonal therapy allowed

    • May be initiated before, during, or after radiotherapy
  • No other concurrent chemotherapy, immunotherapy, or experimental medications
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00909909

United States, New Jersey
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States, 08903
Sponsors and Collaborators
University of Medicine and Dentistry of New Jersey
Principal Investigator: Atif Khan, MD Rutgers Cancer Institute of New Jersey
  More Information

Additional Information:
No publications provided

Responsible Party: Rutgers, The State University of New Jersey ( University of Medicine and Dentistry of New Jersey )
ClinicalTrials.gov Identifier: NCT00909909     History of Changes
Other Study ID Numbers: 040807, CDR0000643276, P30CA072720
Study First Received: May 28, 2009
Last Updated: August 23, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Rutgers, The State University of New Jersey:
ductal breast carcinoma in situ
invasive ductal breast carcinoma
invasive lobular breast carcinoma
medullary ductal breast carcinoma with lymphocytic infiltrate
mucinous ductal breast carcinoma
papillary ductal breast carcinoma
tubular ductal breast carcinoma
stage I breast cancer
stage II breast cancer
stage IIIA breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on September 29, 2014